Value
4.9/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 2.9 |
| Fwd P/E | 2.7 |
| PEG | 10.0 |
| Analyst target | 6.0 |
- ▸Forward P/E: 42.7x
- ▸PEG: 0.22
MDGL · Why this verdict
Why Madrigal Pharmaceuticals (MDGL) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The two quarters ending November 2025 and February 2026 both missed consensus by wide margins — approximately 149% and 192% below estimates respectively — before a strong beat in the most recent quarter, leaving the earnings track record mixed and near-term forecasts uncertain. Earnings | The next three consecutive quarters each beat consensus, demonstrating that the most recent beat marked a durable turn in execution rather than a one-off. | →Stable |
| CounterLoss-stage biotechs routinely have volatile quarterly results that reflect commercial investment timing rather than structural failure; the most recent large beat may signal that the commercial ramp has found its rhythm and the prior misses were launch-phase anomalies. | ||
Revenue is expanding at 127% per year, placing the company at the top of its peer cohort for growth and reflecting strong early commercial traction for the lead product. Growth breakdown | Revenue growth sustains above 50% per year over the next four quarters as the commercial launch ramp continues. | →Stable |
| CounterHyper-growth rates at commercial launch are inherently front-loaded as the initial patient population converts early; the rate will almost certainly decelerate as the highest-likelihood-to-treat cohort is exhausted, and the pace of deceleration may be faster than consensus models. | ||
All commercial revenues depend on a single approved therapy; any safety signal, label restriction, or competitive entry addressing the same patient population would have an outsized negative impact on the entire business. Bear case | A second product candidate advances toward approval or commercial launch within 24 months, reducing single-product dependency over time. | →Stable |
| CounterConcentrated early-stage commercial focus is typical for a company at this development stage; management resources are often best deployed deepening penetration of the current approved indication rather than spreading across multiple assets. | ||
Analyst consensus implies approximately 18% upside to the current price, supported by a risk/reward ratio of approximately 2.6-to-1 that meets the asymmetry threshold — but a 20% short interest reflects significant institutional skepticism that could amplify volatility in either direction. Sentiment breakdown | Short interest declines below 12% over the next two quarters as consecutive earnings beats reduce bear conviction, lowering the volatility amplifier. | →Stable |
| CounterA high short interest among sophisticated institutional investors may reflect access to clinical or commercial intelligence not yet visible in public disclosures; if the bears are right, the short position acts as directional confirmation rather than a contrarian signal. | ||
The two quarters ending November 2025 and February 2026 both missed consensus by wide margins — approximately 149% and 192% below estimates respectively — before a strong beat in the most recent quarter, leaving the earnings track record mixed and near-term forecasts uncertain.
→StableEarnings
- Expectation
- The next three consecutive quarters each beat consensus, demonstrating that the most recent beat marked a durable turn in execution rather than a one-off.
CounterLoss-stage biotechs routinely have volatile quarterly results that reflect commercial investment timing rather than structural failure; the most recent large beat may signal that the commercial ramp has found its rhythm and the prior misses were launch-phase anomalies.
Revenue is expanding at 127% per year, placing the company at the top of its peer cohort for growth and reflecting strong early commercial traction for the lead product.
→StableGrowth breakdown
- Expectation
- Revenue growth sustains above 50% per year over the next four quarters as the commercial launch ramp continues.
CounterHyper-growth rates at commercial launch are inherently front-loaded as the initial patient population converts early; the rate will almost certainly decelerate as the highest-likelihood-to-treat cohort is exhausted, and the pace of deceleration may be faster than consensus models.
All commercial revenues depend on a single approved therapy; any safety signal, label restriction, or competitive entry addressing the same patient population would have an outsized negative impact on the entire business.
→StableBear case
- Expectation
- A second product candidate advances toward approval or commercial launch within 24 months, reducing single-product dependency over time.
CounterConcentrated early-stage commercial focus is typical for a company at this development stage; management resources are often best deployed deepening penetration of the current approved indication rather than spreading across multiple assets.
Analyst consensus implies approximately 18% upside to the current price, supported by a risk/reward ratio of approximately 2.6-to-1 that meets the asymmetry threshold — but a 20% short interest reflects significant institutional skepticism that could amplify volatility in either direction.
→StableSentiment breakdown
- Expectation
- Short interest declines below 12% over the next two quarters as consecutive earnings beats reduce bear conviction, lowering the volatility amplifier.
CounterA high short interest among sophisticated institutional investors may reflect access to clinical or commercial intelligence not yet visible in public disclosures; if the bears are right, the short position acts as directional confirmation rather than a contrarian signal.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Madrigal's lead therapy is driving 127% year-over-year revenue growth — the highest rate in its industry cohort — and the risk/reward of approximately 2.6-to-1 remains favorable with 18% upside to the consensus target, but two consecutive earnings misses before the most recent quarter, a 20% short interest, and single-product dependency require evidence of sustained execution before the setup becomes fully compelling.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.5 |
| FCF quality | 0.0 |
| Moat | 6.5 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -14% of revenue
- ▸Rule of 40: 113 (elite)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 127% YoY
Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.3 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.3 |
- ▸Overbought (RSI 74)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.4/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.0 |
| Analyst rating | 8.6 |
| Price target | 8.5 |
- ▸LLM news sentiment: +0.60 (n=1)
- ▸Analyst upside: 29%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $3,880,697 (0.032% of mkt cap)
Peer rank
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 2.7 |
| growth rank | 8.7 |
- ▸Industry growth leader
Technical
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.7 |
| support resistance | 2.1 |
| 52w position | 7.2 |
Risk (lower is worse)
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.6 |
| days to cover | 0.0 |
| volatility | 2.5 |
| put call | 7.8 |
| implied vol | 0.9 |
| debt equity | 7.2 |
- ▸High short interest justified: 19%
- ▸High IV: 75%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position. | News modifier -1 (HOLD_IF_HOLDING → SELL_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULT|L3:NEWS_MOD=-1Passed (5)
- MOMENTUM:6.7>=5.5
- INSIDER:OK
- EARNINGS_PROXIMITY:30d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.9<1.5@spot
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.93
Upside
+11.8%
Downside
12.7%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: MOMENTUM:6.7>=5.5. Top dim: Growth at 10.0; weakest: Risk (lower is worse) at 3.3. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Growth at 10.0, Sentiment at 8.4, and Momentum at 6.7; the weakest are Risk (lower is worse) at 3.3, Catalyst at 3.7, and Technical at 3.7. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 0.93 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Industry Leading Revenue Acceleration
Trip ifRevenue growth decelerates below 40% YoY for 2 consecutive quarters, indicating the commercial launch momentum has stalled materially.
- P2Earnings Execution Inconsistency
Trip ifEPS surprise turns negative for 2 consecutive quarters, confirming execution remains unreliable beyond the most recent quarter.
- P3Single Product Regulatory Concentration
Trip ifA second approved product generates more than 15% of quarterly revenue, reducing the single-product concentration risk.
- P4Favorable Upside With High Short Interest
Trip ifShort interest falls below 10% of float for 2 consecutive months, indicating the institutional bear conviction has meaningfully eased.